As resident immune cells of the brain, microglia serve pivotal roles in regulating neuronal function under both physiological and pathological conditions, including aging and the most prevalent neurodegenerative disease, Alzheimer’s disease (AD). Instructed by neurons, microglia regulate synaptic function and guard brain homeostasis throughout life. Dysregulation of microglial function, however, can lead to dire consequences, including aggravated cognitive decline during aging and exacerbated neuropathology in diseases. The triggering receptor expressed on myeloid cells 2 (TREM2) is a key regulator of microglial function. Loss-of-function variants of TREM2 are associated with an increased risk of AD. TREM2 orchestrates the switch of microglial transcriptome programming that modulates microglial chemotaxis, phagocytosis, and inflammatory responses, as well as microglial regulation of synaptic function in health and disease. Intriguingly, the outcome of microglial/TREM2 function is influenced by age and the context of neuropathology. This review summarizes the rapidly growing research on TREM2 under physiological conditions and in AD, particularly highlighting the impact of TREM2 on neuronal function.
AlsemaAMJiangQKrachtLGerritsEDubbelaarMLMiedemaA, and others. 2020. Profiling microglia from Alzheimer’s disease donors and non-demented elderly in acute human post-mortem cortical tissue. Front Mol Neurosci13:134.
2.
AndreoneBJPrzybylaLLlapashticaCRanaADavisSSvan LengerichB, and others. 2020. Alzheimer’s-associated PLCγ2 is a signaling node required for both TREM2 function and the inflammatory response in human microglia. Nat Neurosci23(8):927–38.
3.
AudrainMHaure-MirandeJVWangMHKimSHFanutzaTChakrabartyP, and others. 2019. Integrative approach to sporadic Alzheimer’s disease: deficiency of TYROBP in a tauopathy mouse model reduces C1q and normalizes clinical phenotype while increasing spread and state of phosphorylation of tau. Mol Psychiatry24(9):1383–97.
4.
BemillerSMMcCrayTJAllanKFormicaSVXuGWilsonG, and others. 2017. TREM2 deficiency exacerbates tau pathology through dysregulated kinase signaling in a mouse model of tauopathy. Mol Neurodegener12(1):74.
5.
Boza-SerranoARuizRSanchez-VaroRGarcia-RevillaJYangYJimenez-FerrerI, and others. 2019. Galectin-3, a novel endogenous TREM2 ligand, detrimentally regulates inflammatory response in Alzheimer’s disease. Acta Neuropathol138(2):251–73.
6.
ChengQDanaoJTalrejaSWenPYinJSunN, and others. 2018. TREM2-activating antibodies abrogate the negative pleiotropic effects of the Alzheimer’s disease variant Trem2(R47H) on murine myeloid cell function. J Biol Chem293(32):12620–33.
7.
ColonnaMWangY.2016. TREM2 variants: new keys to decipher Alzheimer disease pathogenesis. Nat Rev Neurosci17(4):201–7.
8.
DawsMRSullamPMNiemiECChenTTTchaoNKSeamanWE. 2003. Pattern recognition by TREM-2: binding of anionic ligands. J Immunol171(2):594–9.
9.
Del-AguilaJLBenitezBALiZDubeUMihindukulasuriyaKABuddeJP, and others. 2019. TREM2 brain transcript-specific studies in AD and TREM2 mutation carriers. Mol Neurodegener14(1):18.
10.
DeussingMBlumeTZottBShiYKleinbergerGFockeC, and others. 2019. Increasing fibrillar amyloidosis is associated with improved cognition and synaptic preservation caused by microglia modulation. J Nucl Med60(Suppl 1):53.
11.
FasslerMRappaportMSCunoCBGeorgeJ.2021. Engagement of TREM2 by a novel monoclonal antibody induces activation of microglia and improves cognitive function in Alzheimer’s disease models. J Neuroinflammation18(1):19.
12.
FilipelloFMoriniRCorradiniIZerbiVCanziAMichalskiB, and others. 2018. The microglial innate immune receptor TREM2 is required for synapse elimination and normal brain connectivity. Immunity48(5):979–991.e8.
13.
ForaboscoPRamasamyATrabzuniDWalkerRSmithCBrasJ, and others. 2013. Insights into TREM2 biology by network analysis of human brain gene expression data. Neurobiol Aging34(12):2699–714.
14.
FrigerioCSWolfsLFattorelliNThruppNVoytyukISchmidtI, and others. 2019. The major risk factors for Alzheimer’s disease: age, sex, and genes modulate the microglia response to Aβ plaques. Cell Rep27(4):1293–1306.e6.
15.
Gabande-RodriguezEKeaneLCapassoM.2020. Microglial phagocytosis in aging and Alzheimer’s disease. J Neurosci Res98(2):284–98.
16.
GefenTKimGBolbolanKGeolyAOhmDOboudiyatC, and others. 2019. Activated microglia in cortical white matter across cognitive aging trajectories. Front Aging Neurosci11:94.
17.
GratuzeMLeynsCESauerbeckADSt-PierreM-KXiongMKimN, and others. 2020. Impact of TREM2 R47H variant on tau pathology-induced gliosis and neurodegeneration. J Clin Invest130(9):4954–68.
18.
GratuzeMLeynsCEGHoltzmanDM. 2018. New insights into the role of TREM2 in Alzheimer’s disease. Mol Neurodegener13(1):66.
19.
GriciucAPatelSFedericoANChoiSHInnesBJOramMK, and others. 2019. TREM2 acts downstream of CD33 in modulating microglial pathology in Alzheimer’s disease. Neuron103(5):820–835.e7.
20.
GuerreiroRWojtasABrasJCarrasquilloMRogaevaEMajounieE, and others. 2013. TREM2 variants in Alzheimer’s disease. N Engl J Med368(2):117–27.
21.
Hall-RobertsHAgarwalDObstJSmithTBMonzon-SandovalJDi DanielE, and others. 2020. TREM2 Alzheimer’s variant R47H causes similar transcriptional dysregulation to knockout, yet only subtle functional phenotypes in human iPSC-derived macrophages. Alzheimers Res Ther12(1):151.
22.
Haure-MirandeJVAudrainMFanutzaTKimSHKleinWLGlabeC, and others. 2017. Deficiency of TYROBP, an adapter protein for TREM2 and CR3 receptors, is neuroprotective in a mouse model of early Alzheimer’s pathology. Acta Neuropathol134(5):769–88.
23.
HeZGuoJLMcBrideJDNarasimhanSKimHChangolkarL, and others. 2018. Amyloid-beta plaques enhance Alzheimer’s brain tau-seeded pathologies by facilitating neuritic plaque tau aggregation. Nat Med24(1):29–38.
24.
JadhavVSLinPBCPenningtonTDi PriscoGVJannuAJXuG, and others. 2020. Trem2 Y38C mutation and loss of Trem2 impairs neuronal synapses in adult mice. Mol Neurodegener15(1):62.
25.
JayTRHirschAMBroihierMLMillerCMNeilsonLERansohoffRM, and others. 2017a. Disease progression-dependent effects of TREM2 deficiency in a mouse model of Alzheimer’s disease. J Neurosci37(3):637–47.
26.
JayTRMillerCMChengPJGrahamLCBemillerSBroihierML, and others. 2015. TREM2 deficiency eliminates TREM2+ inflammatory macrophages and ameliorates pathology in Alzheimer’s disease mouse models. J Exp Med212(3):287–95.
27.
JayTRvon SauckenVELandrethGE. 2017b. TREM2 in neurodegenerative diseases. Mol Neurodegener12(1):56.
28.
JayTRvon SauckenVEMunozBCodocedoJFAtwoodBKLambBT, and others. 2019. TREM2 is required for microglial instruction of astrocytic synaptic engulfment in neurodevelopment. Glia67(10):1873–92.
29.
JonssonTStefanssonHSteinbergSJonsdottirIJonssonPVSnaedalJ, and others. 2013. Variant of TREM2 associated with the risk of Alzheimer’s disease. N Engl J Med368(2):107–16.
30.
KanekoMSanoKNakayamaJAmanoN.2010. Nasu-Hakola disease: the first case reported by Nasu and review: The 50th Anniversary of Japanese Society of Neuropathology. Neuropathology30(5):463–70.
31.
KangSSKurtiABakerKELiuCCColonnaMUlrichJD, and others. 2018. Behavioral and transcriptomic analysis of Trem2-null mice: not all knockout mice are created equal. Hum Mol Genet27(2):211–23.
32.
Keren-ShaulHSpinradAWeinerAMatcovitch-NatanODvir-SzternfeldRUllandTK, and others. 2017. A unique microglia type associated with restricting development of Alzheimer’s disease. Cell169(7):1276–1290.e17.
33.
KimSMMunBRLeeSJJohYLeeHYJiKY, and others. 2017. TREM2 promotes Aβ phagocytosis by upregulating C/EBPα-dependent CD36 expression in microglia. Sci Rep7(1):11118.
34.
KoberDLBrettTJ. 2017. TREM2-ligand interactions in health and disease. J Mol Biol429(11):1607–29.
35.
KonishiHKiyamaH.2018. Microglial TREM2/DAP12 signaling: a double-edged sword in neural diseases. Front Cell Neurosci12:206.
36.
KorvatskaOLeverenzJBJayadevSMcMillanPKurtzIGuoX, and others. 2015. R47H variant of TREM2 associated with Alzheimer disease in a large late-onset family: clinical, genetic, and neuropathological study. JAMA Neurol72(8):920–7.
37.
KrasemannSMadoreCCialicRBaufeldCCalcagnoNEl FatimyR, and others. 2017. The TREM2-APOE pathway drives the transcriptional phenotype of dysfunctional microglia in neurodegenerative diseases. Immunity47(3):566–581.e9.
LeeSHMeilandtWJXieLGandhamVDNguHBarckKH, and others. 2021. Trem2 restrains the enhancement of tau accumulation and neurodegeneration by β-amyloid pathology. Neuron109(8):1283–1301.e6.
40.
LeynsCEGGratuzeMNarasimhanSJainNKoscalLJJiangH, and others. 2019. TREM2 function impedes tau seeding in neuritic plaques. Nat Neurosci22(8):1217–22.
41.
LeynsCEGUlrichJDFinnMBStewartFRKoscalLJRemolina SerranoJ, and others. 2017. TREM2 deficiency attenuates neuroinflammation and protects against neurodegeneration in a mouse model of tauopathy. Proc Natl Acad Sci U S A114(43):11524–9.
42.
LillCMRengmarkAPihlstromLFoghIShatunovASleimanPM, and others. 2015. The role of TREM2 R47H as a risk factor for Alzheimer’s disease, frontotemporal lobar degeneration, amyotrophic lateral sclerosis, and Parkinson’s disease. Alzheimers Dement11(12):1407–16.
43.
Linnartz-GerlachBBodeaLGKlausCGinolhacAHalderRSinkkonenL, and others. 2019. TREM2 triggers microglial density and age-related neuronal loss. Glia67(3):539–50.
44.
LueLFSchmitzCTSerranoGSueLIBeachTGWalkerDG. 2015. TREM 2 protein expression changes correlate with Alzheimer’s disease neurodegenerative pathologies in post-mortem temporal cortices. Brain Pathol25(4):469–80.
45.
MaesMEColomboGSchulzRSiegertS.2019. Targeting microglia with lentivirus and AAV: recent advances and remaining challenges. Neurosci Lett707:134310.
46.
McQuadeAKangYJHasselmannJJairamanASoteloACoburnM, and others. 2020. Gene expression and functional deficits underlie TREM2-knockout microglia responses in human models of Alzheimer’s disease. Nat Commun11(1):5370.
47.
MeilandtWJNguHGogineniALalehzadehGLeeSHSrinivasanK, and others. 2020. Trem2 deletion reduces late-stage amyloid plaque accumulation, elevates the Aβ42:Aβ40 ratio, and exacerbates axonal dystrophy and dendritic spine loss in the PS2APP Alzheimer’s mouse model. J Neurosci40(9):1956–74.
48.
NugentAALinKvan LengerichBLianoglouSPrzybylaLDavisSS, and others. 2020. TREM2 regulates microglial cholesterol metabolism upon chronic phagocytic challenge. Neuron105(5):837–854.e9.
49.
OlahMMenonVHabibNTagaMFMaYYungCJ, and others. 2020. Single cell RNA sequencing of human microglia uncovers a subset associated with Alzheimer’s disease. Nat Commun11(1):6129.
50.
OteroKTurnbullIRPolianiPLVermiWCeruttiEAoshiT, and others. 2009. Macrophage colony-stimulating factor induces the proliferation and survival of macrophages via a pathway involving DAP12 and β-catenin. Nat Immunol10(7):734–43.
51.
PainterMMAtagiYLiuCCRademakersRXuHFryerJD, and others. 2015. TREM2 in CNS homeostasis and neurodegenerative disease. Mol Neurodegener10(1):43.
52.
ParhizkarSArzbergerTBrendelMKleinbergerGDeussingMFockeC, and others. 2019. Loss of TREM2 function increases amyloid seeding but reduces plaque-associated ApoE. Nat Neurosci22(2):191–204.
53.
PluvinageJVHaneyMSSmithBAHSunJIramTBonannoL, and others. 2019. CD22 blockade restores homeostatic microglial phagocytosis in ageing brains. Nature568(7751):187–92.
54.
PolianiPLWangYFontanaERobinetteMLYamanishiYGilfillanS, and others. 2015. TREM2 sustains microglial expansion during aging and response to demyelination. J Clin Invest125(5):2161–70.
55.
PriceBRSudduthTLWeekmanEMJohnsonSHawthorneDWoolumsA, and others. 2020. Therapeutic Trem2 activation ameliorates amyloid-β deposition and improves cognition in the 5XFAD model of amyloid deposition. J Neuroinflammation17(1):238.
56.
QuWLiL.2020. Loss of TREM2 confers resilience to synaptic and cognitive impairment in aged mice. J Neurosci40(50):9552–63.
57.
RayWJBuggia-PrevotV.2021. Novel targets for Alzheimer’s disease: a view beyond amyloid. Annu Rev Med72:15–28.
58.
RenSYaoWTambiniMDYinTNorrisKAD’AdamioL.2020. Microglia TREM2(R47H) Alzheimer-linked variant enhances excitatory transmission and reduces LTP via increased TNF-α levels. Elife9:e57513.
59.
RoumierAPascualOBechadeCWakselmanSPoncerJCRealE, and others. 2008. Prenatal activation of microglia induces delayed impairment of glutamatergic synaptic function. PLoS One3(7):e2595.
60.
SalterMWStevensB.2017. Microglia emerge as central players in brain disease. Nat Med23(9):1018–27.
61.
SayedFATelpoukhovskaiaMKodamaLLiYZhouYLeD, and others. 2018. Differential effects of partial and complete loss of TREM2 on microglial injury response and tauopathy. Proc Natl Acad Sci U S A115(40):10172–7.
62.
SchlepckowKMonroeKMKleinbergerGCantuti-CastelvetriLParhizkarSXiaD, and others. 2020. Enhancing protective microglial activities with a dual function TREM 2 antibody to the stalk region. EMBO Mol Med12(4):e11227.
63.
ShengLChenMCaiKSongYYuDZhangH, and others. 2019. Microglial Trem2 induces synaptic impairment at early stage and prevents amyloidosis at late stage in APP/PS1 mice. FASEB J33(9):10425–42.
64.
ShiYHoltzmanDM. 2018. Interplay between innate immunity and Alzheimer disease: APOE and TREM2 in the spotlight. Nat Rev Immunol18(12):759–72.
65.
ShobinEBowleyMPEstradaLIHeyworthNCOrczykowskiMEEldridgeSA, and others. 2017. Microglia activation and phagocytosis: relationship with aging and cognitive impairment in the rhesus monkey. Geroscience39(2):199–220.
66.
SquarzoniPOllerGHoeffelGPont-LezicaLRostaingPLowD, and others. 2014. Microglia modulate wiring of the embryonic forebrain. Cell Rep8(5):1271–9.
67.
TakaloMWittrahmRWefersBParhizkarSJokivarsiKKuulasmaaT, and others. 2020. The Alzheimer’s disease-associated protective Plcγ2-P522R variant promotes immune functions. Mol Neurodegener15(1):52.
68.
TaoCCChengKMMaYLHsuWLChenYCFuhJL, and others. 2020. Galectin-3 promotes Aβ oligomerization and Aβ toxicity in a mouse model of Alzheimer’s disease. Cell Death Differ27(1):192–209.
69.
ThrashJCTorbettBECarsonMJ. 2009. Developmental regulation of TREM2 and DAP12 expression in the murine CNS: implications for Nasu-Hakola disease. Neurochem Res34(1):38–45.
UllandTKColonnaM.2018. TREM2—a key player in microglial biology and Alzheimer disease. Nat Rev Neurol14(11):667–75.
72.
UlrichJDFinnMBWangYShenAMahanTEJiangH, and others. 2014. Altered microglial response to Aβ plaques in APPPS1-21 mice heterozygous for TREM2. Mol Neurodegener9:20.
73.
UlrichJDUllandTKMahanTENystromSNilssonKPSongWM, and others. 2018. ApoE facilitates the microglial response to amyloid plaque pathology. J Exp Med215(4):1047–58.
74.
VogelsTMurgociANHromadkaT.2019. Intersection of pathological tau and microglia at the synapse. Acta Neuropathol Commun7(1):109.
75.
WakselmanSBechadeCRoumierABernardDTrillerABessisA.2008. Developmental neuronal death in hippocampus requires the microglial CD11b integrin and DAP12 immunoreceptor. J Neurosci28(32):8138–43.
76.
WangSMustafaMYuedeCMSalazarSVKongPLongH, and others. 2020. Anti-human TREM2 induces microglia proliferation and reduces pathology in an Alzheimer’s disease model. J Exp Med217(9):e20200785.
77.
WangYCellaMMallinsonKUlrichJDYoungKLRobinetteML, and others. 2015. TREM2 lipid sensing sustains the microglial response in an Alzheimer’s disease model. Cell160(6):1061–71.
78.
WangYUllandTKUlrichJDSongWTzaferisJAHoleJT, and others. 2016. TREM2-mediated early microglial response limits diffusion and toxicity of amyloid plaques. J Exp Med213(5):667–75.
79.
WuMLiaoMHuangRChenCTianTWangH, and others. 2020. Hippocampal overexpression of TREM2 ameliorates high fat diet induced cognitive impairment and modulates phenotypic polarization of the microglia. Genes Dis. Epub May 21. doi:10.1016/j.gendis.2020.05.005
80.
XuRLiXBorelandAJPosytonAKwanKHartRP, and others. 2020. Human iPSC-derived mature microglia retain their identity and functionally integrate in the chimeric mouse brain. Nat Commun11(1):1577.
81.
YuanPCondelloCKeeneCDWangYBirdTDPaulSM, and others. 2016. TREM2 haplodeficiency in mice and humans impairs the microglia barrier function leading to decreased amyloid compaction and severe axonal dystrophy. Neuron90(4):724–39.
82.
ZhengHJiaLLiuCCRongZZhongLYangL, and others. 2017. TREM2 promotes microglial survival by activating Wnt/β-catenin pathway. J Neurosci37(7):1772–84.
83.
ZhongLChenX-FWangTWangZLiaoCWangZ, and others. 2017. Soluble TREM2 induces inflammatory responses and enhances microglial survival. J Exp Med214(3):597–607.
84.
ZhongLChenXF. 2019. The emerging roles and therapeutic potential of soluble TREM2 in Alzheimer’s disease. Front Aging Neurosci11:328.
85.
ZhouYSongWMAndheyPSSwainALevyTMillerKR, and others. 2020. Human and mouse single-nucleus transcriptomics reveal TREM2-dependent and TREM2-independent cellular responses in Alzheimer’s disease. Nat Med26(1):131–42.
